CYDY — Cytodyn Cashflow Statement
0.000.00%
- $400.42m
- $411.16m
- 16
- 68
- 89
- 59
Annual cashflow statement for Cytodyn, fiscal year end - May 31st, USD millions except per share, conversion factor applied.
2020 May 31st | 2021 May 31st | 2022 May 31st | 2023 May 31st | 2024 May 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -124 | -155 | -211 | -79.8 | -49.8 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | 55.2 | 55.4 | 137 | 35.1 | 27.2 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -1.59 | -20.1 | -4.78 | 19.4 | 11.7 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Cash from Operating Activities | -68.8 | -118 | -77.7 | -25.1 | -11 |
Capital Expenditures | -0.041 | -0.122 | 0 | — | — |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | — | — | — | 0 | — |
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.041 | -0.122 | 0 | 0 | — |
Financing Cash Flow Items | -3.24 | 16.3 | 5.39 | 2.81 | 0.3 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 79.7 | 137 | 48 | 29.9 | 11.7 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 10.8 | 19.7 | -29.7 | 4.82 | 0.766 |